Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | G6PD | P11413 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14802348 | 1.00 | G6PD (0.33) | G6PD | |
| SCHEMBL15293425 | 1.00 | G6PD (0.33) | G6PD | |
| SCHEMBL17154136 | 0.88 | LGALS8 (0.39) | — | |
| SCHEMBL14802349 | 0.88 | LGALS8 (0.39) | — | |
| SCHEMBL15293443 | 0.88 | LGALS8 (0.39) | — | |
| SCHEMBL15267331 | 0.88 | G6PD (0.33) | G6PD | |
| SCHEMBL15267333 | 0.88 | G6PD (0.33) | G6PD | |
| SCHEMBL18857528 | 0.88 | G6PD (0.37) | G6PD | |
| SCHEMBL16587783 | 0.86 | — | — | |
| SCHEMBL15293456 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987430-B2 | Efficient and scalable process for the manufacture of fondaparinux sodium | RELIABLE BIOPHARMACEUTICAL CORPORATION (US) | 2015-03-24 | — | — | US | disclosed |
| US-20130261291-A1 | EFFICIENT AND SCALABLE PROCESS FOR THE MANUFACTURE OF FONDAPARINUX SODIUM | RELIABLE BIOPHARMACEUTICAL CORPORATION (US) | 2013-10-03 | — | — | US | disclosed |
| US-8420790-B2 | Efficient and scalable process for the manufacture of Fondaparinux sodium | RELIABLE BIOPHARMACEUTICAL CORPORATION (US) | 2013-04-16 | — | — | US | disclosed |
| US-20120116066-A1 | EFFICIENT AND SCALABLE PROCESS FOR THE MANUFACTURE OF FONDAPARINUX SODIUM | RELIABLE BIOPHARMACEUTICAL CORPORATION (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120116066-A1 | EFFICIENT AND SCALABLE PROCESS FOR THE MANUFACTURE OF FONDAPARINUX SODIUM | F11, F10, F2 | G6PD 309/4885 |
| US-20130261291-A1 | EFFICIENT AND SCALABLE PROCESS FOR THE MANUFACTURE OF FONDAPARINUX SODIUM | F11, F10, F2 | G6PD 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.